Literature DB >> 10099000

Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Italian Group for Cystic Fibrosis microbiology.

G Taccetti1, S Campana, L Marianelli.   

Abstract

We carried out an epidemiological study on 2717 patients seen on a regular basis at Italian Cystic Fibrosis Centers with the aim of defining the prevalence of multiresistant Gram-negative strains in Italy. We found 272 multiresistant strains out of 1560 Gram-negative strains isolated in 1012 Italian cystic fibrosis patients. From our results in Italian cystic fibrosis patients we may conclude: (1) the beta-lactam antibiotics are moderately active; ceftazidime is the most efficacious even if 59.9% of multiresistant strains are not sensitive to this drug; (2) the aminoglycosides are poorly efficacious; 93% of multiresistant strains are resistant in vitro to tobramycin; and (3) the quinolones, notwithstanding their relatively recent introduction into clinical practice, have very poor activity against multiresistant strains, 89.7% of which are not sensitive.

Entities:  

Mesh:

Year:  1999        PMID: 10099000     DOI: 10.1023/a:1007504524034

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  11 in total

1.  Microbiologic data overview of Italian cystic fibrosis patients.

Authors:  G Taccetti; S Campana
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

Review 2.  Cystic fibrosis.

Authors:  P B Davis; M Drumm; M W Konstan
Journal:  Am J Respir Crit Care Med       Date:  1996-11       Impact factor: 21.405

3.  Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.

Authors:  P Vandamme; B Holmes; M Vancanneyt; T Coenye; B Hoste; R Coopman; H Revets; S Lauwers; M Gillis; K Kersters; J R Govan
Journal:  Int J Syst Bacteriol       Date:  1997-10

4.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.

Authors:  A Isles; I Maclusky; M Corey; R Gold; C Prober; P Fleming; H Levison
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

5.  Burkholderia (Pseudomonas) cepacia epidemiology in a cystic fibrosis population: a genome finger-printing study.

Authors:  G Cazzola; G Amalfitano; E Tonolli; C Perazzoli; I Piacentini; G Mastella
Journal:  Acta Paediatr       Date:  1996-05       Impact factor: 2.299

Review 6.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

Review 7.  Microbiology of lung infection in cystic fibrosis.

Authors:  J R Govan; J W Nelson
Journal:  Br Med Bull       Date:  1992-10       Impact factor: 4.291

8.  Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

Authors:  K Cheng; R L Smyth; J R Govan; C Doherty; C Winstanley; N Denning; D P Heaf; H van Saene; C A Hart
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

Review 9.  New antimicrobial agents.

Authors:  J Goldfarb
Journal:  Pediatr Clin North Am       Date:  1995-06       Impact factor: 3.278

10.  The changing epidemiology of cystic fibrosis.

Authors:  S C FitzSimmons
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

View more
  8 in total

1.  Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status.

Authors:  A Agodi; E Mahenthiralingam; M Barchitta; V Gianninò; A Sciacca; S Stefani
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

2.  Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.

Authors:  William A Prescott; Allison E Gentile; Jerod L Nagel; Rebecca S Pettit
Journal:  P T       Date:  2011-11

Review 3.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

4.  In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.

Authors:  John J LiPuma; Sivaprakash Rathinavelu; Bridget K Foster; Jordan C Keoleian; Paul E Makidon; Linda M Kalikin; James R Baker
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

5.  Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; S B Duffull; M Kinzig-Schippers; U Holzgrabe; U Stephan; G L Drusano; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

6.  Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.

Authors:  T L Pitt; M Sparrow; M Warner; M Stefanidou
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

7.  Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; C B Landersdorfer; S J Hüttner; G L Drusano; M Kinzig; U Holzgrabe; U Stephan; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

Review 8.  Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy.

Authors:  Cordula Koerner-Rettberg; Manfred Ballmann
Journal:  Core Evid       Date:  2014-09-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.